Trial Profile

A Multicenter, Randomized, Double-Blind Phase 3 Study Of Palbociclib (Oral CDK 4/6 Inhibitor) Plus Letrozole Versus Placebo Plus Letrozole For The Treatment Of Previously Untreated Asian Postmenopausal Women With ER(+), HER2 (-) Advanced Breast Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 23 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Palbociclib (Primary) ; Letrozole
Indications Advanced breast cancer; HER2 negative breast cancer; HER2 positive breast cancer
Focus Registrational; Therapeutic Use
Acronyms PALOMA-4
Sponsors Pfizer

21 Oct 2024 Planned End Date changed from 31 Dec 2024 to 28 Feb 2025.
03 May 2023 Planned End Date changed from 2 Dec 2022 to 31 Dec 2024.
22 Sep 2022 Primary results reporting efficacy and safety data in postmenopausal Asian women with ER+/HER2- advanced breast cancer published in the European Journal of Cancer

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com